Medical Learning Hub  welcomes you to a live clinical experience sharing webinar on the topic  “Covid-19 - Surgeons view and Use of Remdesivir in Renal and Hepatic Dysfunction” 
Module 1: The webinar began with the introduction of the speakers. A pre-poll was raised and attempted by the delegates. The flow of the webinar was explained. 
Module 2 : ( 8:00) Dr. Revanth Gangasani Reddy: Covid-19, Surgeons Point of View 
• Dr. Revanth discussed the Covid-19 in brief. He explained the necessity for a surgeon to be aware of the preventive measures during procedures. 
• Death of health care workers and correlation to lack of preventive measures explained. 
• Protocol for prevention established by American College of Surgeons, Royal College of Surgeons of England, Society American Gastrointestinal Endoscopic Surgeons and Ambulatory Surgery Center Association discussed.
• Dr. Revanth explained the protocol for prevention of transmission during COVID-19 in detail established by The Association of Surgeons of India. General instructions for surgeons during procedure and categorization of patients with respect to necessity discussed. 
• The types of PPE to be used according to different services, exposure, and place in the hospital discussed 
• Recommendation's on surgical practices for postponement of surgeries discussed 
• The risk of various types of surgeries discussed 
• Post-surgery complications and diagnosis explained 
• The protocols before during and after surgery and forms used at the hospital discussed and explained 
• Type of preferred anesthesia and Doffing - Donning sequence discussed 
Module 3 : (44:00 ) Dr. Vajrapu Rajendra Use of Remdesivir in Renal and Hepatic Dysfunction 
• Dr. Rajendra described in brief Remdesivir and its use and required renal and hepatic tests reports requirements 
• Pharmacokinetics of Remdesivir was described with respect to renal excretion and breakdown 
• Acute kidney injury (AKI) resulting in COVID-19 described and indications to use remdesivir in AKI and post-renal transplant patients discussed 
• Dosage of Remdesivir in extracorporeal circuits explained 
• Dosage and use of Remdesivir in patients with liver dysfunction discussed in relation to laboratory results 
• Liver injury resulting in COVID-19 described and indications to use remdesivir 
Module 4 : ( 1:13:00) The webinar concluded with an interactive question-answer session followed by a post-poll and vote of thanks.
We thank  Viatris for making this event possible and we wish you all a great learning experience.